Atlas Capital Advisors Inc. Takes Position in Merck & Co., Inc. $MRK

Atlas Capital Advisors Inc. bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,992 shares of the company’s stock, valued at approximately $631,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. D.A. Davidson & CO. increased its stake in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after acquiring an additional 32,114 shares during the last quarter. Coldstream Capital Management Inc. increased its stake in Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after acquiring an additional 13,940 shares during the last quarter. NEOS Investment Management LLC increased its stake in Merck & Co., Inc. by 39.9% during the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after acquiring an additional 99,074 shares during the last quarter. Finally, Campbell Capital Management Inc. acquired a new stake in Merck & Co., Inc. during the third quarter worth $1,866,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on MRK. JPMorgan Chase & Co. raised their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Citigroup began coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Wells Fargo & Company cut their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Trading Up 0.0%

Shares of NYSE MRK opened at $119.05 on Monday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a fifty day simple moving average of $116.55 and a 200-day simple moving average of $113.32. The stock has a market capitalization of $294.04 billion, a PE ratio of 33.54, a PEG ratio of 2.68 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the firm posted $2.22 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.